翰森制药午前涨超4% 阿美乐 获批第五项适应症 辅助治疗研究登上《柳叶刀·肿瘤学》

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication approval for its innovative drug, Amelot (Ametinib Mesylate Tablets) by the National Medical Products Administration (NMPA) in China [1] Group 1: Drug Approval and Indications - On January 8, Hansoh Pharmaceutical announced that Amelot received a drug registration certificate from NMPA, approving its use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth approved indication for Amelot, highlighting the drug's expanding therapeutic potential in oncology [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal, Lancet Oncology, indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, with a favorable safety profile [1]